![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1403348
¼¼°èÀÇ ½ÉÇ÷°ü°è ±â±â ½ÃÀå ¿¹Ãø(-2030³â) : ±â±â À¯Çü, ¿ëµµ, ÃÖÁ¾ »ç¿ëÀÚ ¹× Áö¿ªº° ºÐ¼®Cardiovascular Devices Market Forecasts to 2030 - Global Analysis By Device Type, Application (Coronary Artery Disease, Heart Failure, Cardiac Arrhythmia and Other Applications), End User and By Geography |
¼¼°è ½ÉÇ÷°ü ÀåÄ¡ ½ÃÀå ±Ô¸ð´Â 2023³â 656¾ï 6,000¸¸ ´Þ·¯¿¡ À̸£°í, 2030³â 1,271¾ï 5,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾È 9.9%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
½ÉÇ÷°ü°è ±â±â´Â Áúº´ ¹× ¼øÈ¯±â °èÅëÀÇ Áø´Ü, Ä¡·á, ¸ð´ÏÅ͸µÀ» ¸ñÀûÀ¸·Î ÇÏ´Â ÀÇ·á±â±âÀÔ´Ï´Ù. ºÎÁ¤¸Æ, °ü»óµ¿¸ÆÁúȯ, ½ÉºÎÀü µî ´Ù¾çÇÑ ½ÉÇ÷°ü°è ÁúȯÀ» Ä¡·áÇÔÀ¸·Î½á ÀÇ·á¿¡¼ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ½É¹ÚÁ¶À²±â, Á¦¼¼µ¿±â, ¿µ»óÁø´ÜÀåÄ¡, ¸ð´ÏÅ͸µ ½Ã½ºÅÛ, Ä«Å×ÅÍ µîÀÌ ´ëÇ¥ÀûÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ÀåºñÀÇ Á߿伺Àº È¿°úÀûÀÎ Ä¡·á¹ýÀ» Á¦°øÇϰí, Á¤È®ÇÑ Áø´ÜÀ» ¿ëÀÌÇÏ°Ô Çϸç, ȯÀÚÀÇ °á°ú¸¦ °³¼±ÇÒ ¼ö ÀÖ´Â ´É·Â¿¡¼ ºñ·ÔµË´Ï´Ù.
¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é, ½ÉÇ÷°ü ÁúȯÀ¸·Î ÀÎÇÑ »ç¸ÁÀÇ ¾à 75%´Â ÁßÀú¼Òµæ ±¹°¡¿¡¼ ¹ß»ýÇÕ´Ï´Ù.
½ÉÇ÷°ü ÁúȯÀÇ À¯º´·ü Áõ°¡
½ÉºÎÀü, ºÎÁ¤¸Æ, °ü»óµ¿¸ÆÁúȯ(CADD)°ú °°Àº ½ÉÇ÷°üÁúȯ(CVD)ÀÇ À¯º´·ü Áõ°¡´Â ÁÂ½Ä »ýȰ½À°ü, °Ç°¿¡ ÇØ·Î¿î ½Ä½À°ü, Èí¿¬, °í·ÉÈ µî ¿©·¯ °¡Áö ¿äÀο¡ ±âÀÎÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Áúº´ ºÎ´ã Áõ°¡´Â Çõ½ÅÀûÀÎ ½ÉÇ÷°ü ±â±â ¹× ±â¼ú¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ½É¹æ¼¼µ¿Á¦¼¼µ¿±â(ICD), ½É¹ÚÁ¶À²±â, ¾à¹°¿ëÃâ ½ºÅÙÆ®, ½ÉÀå ¸ð´ÏÅ͸µ ÀåÄ¡¿Í °°Àº ÀåÄ¡´Â ´Ù¾çÇÑ ½ÉÇ÷°ü ÁúȯÀÇ Áø´Ü, Ä¡·á ¹× °ü¸®¿¡ ÀÖ¾î ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Ã·´Ü ±â¼úÀº ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±Çϰí, »ç¸Á·üÀ» ³·Ã߸ç, ȯÀÚÀÇ Àü¹ÝÀûÀÎ »îÀÇ ÁúÀ» Çâ»ó½ÃŰ´Â µ¥ µµ¿òÀ» ÁÖ°í ÀÖ½À´Ï´Ù. µû¶ó¼ ½ÃÀå È®´ë¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.
¿¬±¸ °³¹ß Ȱµ¿ÀÇ À庮 Áõ°¡
±ÔÁ¦ ´ç±¹ÀÇ ¸ð´ÏÅ͸µÀÌ °ÈµÇ°í, ¾ÈÀü ±âÁØÀÌ °ÈµÇ°í, ´ë±Ô¸ð ÀÓ»ó½ÃÇèÀÌ ÇÊ¿äÇϱ⠶§¹®¿¡ ¿¬±¸°³¹ßºñ¿ë°ú ±â°£ÀÌ Å©°Ô Áõ°¡ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ À庮Àº Áß¼Ò±â¾÷°ú ½ºÅ¸Æ®¾÷¿¡ ºÒ±ÕÇüÀûÀ¸·Î ¿µÇâÀ» ¹ÌÃÄ ½ÃÀå ÁøÀÔ°ú Çõ½Å ´É·ÂÀ» Á¦ÇÑÇϰí ÀÖ½À´Ï´Ù. ±âÁ¸ ±â¾÷µéµµ ¿¬±¸°³¹ß¿¡ ¸¹Àº ÅõÀÚ¸¦ ÇÊ¿ä·Î ÇÏ´Â Àå¾Ö¹°¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ³ôÀº R&D À庮Àº »õ·Î¿î ½ÉÇ÷°ü ÀåÄ¡ÀÇ Àû½Ã µµÀÔÀ» ¹æÇØÇÏ°í ±â¼ú Çõ½Å°ú ½ÃÀå ¼ºÀåÀ» ÀúÇØÇϰí ÀÖ½À´Ï´Ù.
¿ø°ÝÀÇ·á ¹× ¿ø°Ý ¸ð´ÏÅ͸µ
¿ø°Ý ÀÇ·á ¹× ¿ø°Ý ¸ð´ÏÅ͸µÀº »ýü ½ÅÈ£, ½É¹Ú¼ö ¹× ±âŸ °ü·Ã µ¥ÀÌÅ͸¦ ½Ç½Ã°£À¸·Î ¿ø°ÝÀ¸·Î ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖ°Ô ÇÔÀ¸·Î½á ȯÀÚÀÇ Áö¼ÓÀûÀÎ Ä¡·á¸¦ ÃËÁøÇÕ´Ï´Ù. ½ÉÇ÷°ü°è ȯÀÚ¿¡°Ô´Â ÀçÅà ¸ð´ÏÅ͸µÀÇ Æí¸®ÇÔ, º´¿ø ¹æ¹® °¨¼Ò, ÀÇ·á Á¢±Ù¼º Çâ»ó µîÀÇ ÀÌÁ¡ÀÌ ÀÖ½À´Ï´Ù. ÷´Ü ¿þ¾î·¯ºí ±â±â, ¸ð¹ÙÀÏ ¾Û, Ä¿³ØÆ¼µå Ç÷§ÆûÀº ÀÇ·á Àü¹®°¡°¡ ¿ø°ÝÀ¸·Î ȯÀÚÀÇ »óŸ¦ Æò°¡Çϰí, Àû½Ã¿¡ °³ÀÔÇϰí, °³ÀÎ ¸ÂÃãÇü Ä¡·á¸¦ Á¦°øÇÔÀ¸·Î½á ±Ã±ØÀûÀ¸·Î ȯÀÚÀÇ °á°ú¸¦ °³¼±ÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. ¶ÇÇÑ, ½ÉÀåÇп¡¼ ¿ø°Ý ÀÇ·á¿Í ¿ø°Ý ¸ð´ÏÅ͸µÀÇ ÅëÇÕÀº Çõ½ÅÀÇ ±æÀ» ¿¾î ¿ø°Ý ¸ð´ÏÅ͸µ ¹× ¿ø°Ý ÀÇ·á ¿ëµµ¿¡ ¸Â°Ô Á¶Á¤µÈ º¸´Ù Á¤±³ÇÏ°í »ç¿ëÀÚ Ä£ÈÀûÀ̸ç È¿°úÀûÀÎ ½ÉÀåÇÐ ÀåÄ¡ÀÇ °³¹ßÀ» ÃËÁøÇÒ ¼ö ÀÖ½À´Ï´Ù.
¾ö°ÝÇÑ ±ÔÁ¦
³¯·Î ¾ö°ÝÇØÁö´Â ±ÔÁ¦ ¿ä°ÇÀº ½ÂÀÎ ÀýÂ÷°¡ ±æ¾îÁö°í, ±ÔÁ¦ Áؼö ºñ¿ëÀÌ Áõ°¡Çϸç, »õ·Î¿î Àåºñ µµÀÔ¿¡ ´ëÇÑ À庮ÀÌ ³ô¾ÆÁú ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±ÔÁ¦´Â ƯÈ÷ º¹ÀâÇÑ ±ÔÁ¦ ȯ°æÀ» ÇìÃijª°¥ ¼ö ÀÖ´Â ÀÚ¿øÀÌ ºÎÁ·ÇÑ Áß¼Ò±â¾÷ÀÇ °æ¿ì, ±â¼ú Çõ½Å°ú ½ÃÀå ÁøÀÔÀ» ÀúÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ±ÔÁ¦ º¯È¿Í ºÒÈ®½Ç¼ºÀº ±âÁ¸ ½ÃÀå Àü·«°ú ÅõÀÚ¸¦ ¹æÇØÇϰí Á¦Ç° °³¹ß ÀÏÁ¤°ú ½ÃÀå °æÀï·Â¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù.
Äڷγª19´Â ´Ù¾çÇÑ ÇüÅ·Π½ÉÇ÷°ü ±â±â ½ÃÀå¿¡ Å« ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. Ãʱ⿡´Â Àü¿°º´ °ü¸®¿¡ ÁßÁ¡À» µÎ¾î ÀÇ·á ÀÚ¿øÀ» ÀçºÐ¹èÇϰí ÀÀ±Þ Ä¡·á ¿Ü¿¡´Â Ä¡·á¸¦ ¹ÞÁö ¾ÊÀ¸·Á´Â ȯÀÚµé·Î ÀÎÇØ ½ÉÇ÷°ü Áúȯ¿¡ ´ëÇÑ ¼±ÅÃÀû ¼ö¼ú°ú Áø´ÜÀÌ °¨¼ÒÇß½À´Ï´Ù. °ø±Þ¸ÁÀÇ È¥¶õ°ú Á¦Á¶»óÀÇ Á¦¾àµµ ÀåºñÀÇ °¡¿ë¼º¿¡ ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. ±×·¯³ª ÆÒµ¥¹ÍÀº ¿ø°Ý ÀÇ·á ¹× ¿ø°Ý ¸ð´ÏÅ͸µ ¼Ö·ç¼ÇÀÇ Ã¤ÅÃÀ» °¡¼ÓÈÇÏ¿© ½ÉÇ÷°ü Ä¡·á¸¦ À§ÇÑ µðÁöÅÐ °Ç° ±â¼ú Çõ½ÅÀ» ÃËÁøÇß½À´Ï´Ù. ¹é½Å Á¢Á¾·üÀÌ »ó½ÂÇϰí ÀÇ·á ½Ã½ºÅÛÀÌ »õ·Î¿î Á¤»ó »óÅ¿¡ ÀûÀÀÇÔ¿¡ µû¶ó ¼±ÅÃÀû ¼ö¼úÀº Á¡Â÷ ȸº¹µÇ¾ú½À´Ï´Ù.
Áø´Ü ¹× ¸ð´ÏÅ͸µ Àåºñ ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È °¡Àå Å« ½ÃÀåÀ¸·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
Áø´Ü ¹× ¸ð´ÏÅ͸µ ±â±â ºÎ¹®Àº ½ÉÇ÷°ü »óŸ¦ °¨Áö, ¸ð´ÏÅ͸µ ¹× Æò°¡Çϵµ·Ï ¼³°èµÈ ÷´Ü ±â¼ú·Î ÀÎÇØ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ÀÌ·¯ÇÑ ±â±â´Â ½ÉÀå ¸®µë, Ç÷¾Ð ¹× ±âŸ Ȱ·Â ¡Èĸ¦ ½Ç½Ã°£À¸·Î ¸ð´ÏÅ͸µÇÏ¿© ÀÌ»ó ¡Èĸ¦ Á¶±â¿¡ ¹ß°ßÇϰí Áö¼ÓÀûÀΠȯÀÚ Ä¡·á¸¦ ÃËÁøÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÌ·¯ÇÑ ±â±â´Â ´Ù¾çÇÑ ½ÉÇ÷°ü°è ÁúȯÀÇ Áø´Ü¿¡ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϸç, ÀÇ·á Àü¹®°¡¿¡°Ô Á¤È®ÇÑ Æò°¡, °³ÀÎ ¸ÂÃãÇü Ä¡·á Àü·«, ȯÀÚ °á°ú °³¼±À» À§ÇÑ Áß¿äÇÑ µ¥ÀÌÅ͸¦ Á¦°øÇÏ¿© ±Ã±ØÀûÀ¸·Î ½ÉÀå ÁúȯÀ» ´õ Àß °ü¸®Çϰí Ä¡·áÇÏ´Â µ¥ ±â¿©ÇÕ´Ï´Ù.
¿¹Ãø ±â°£ µ¿¾È °ü»óµ¿¸ÆÁúȯ(CAD) ºÎ¹®ÀÌ °¡Àå ³ôÀº CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
°ü»óµ¿¸ÆÁúȯ(CAD) ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È À¯¸®ÇÑ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. °ü»óµ¿¸ÆÁúȯ(CAD)Àº ½ÉÀå¿¡ »ê¼Ò°¡ dzºÎÇÑ Ç÷¾×À» °ø±ÞÇÏ´Â °ü»óµ¿¸ÆÀÌ Á¼¾ÆÁö°Å³ª ¸·È÷´Â °ÍÀ» ¸»ÇÕ´Ï´Ù. CAD Àü¿ë Àåºñ´Â °æÇÇÀû °ü»óµ¿¸ÆÁßÀç¼ú(PCI), °ü»óµ¿¸Æ¿ìȸ¼ú(CABG)°ú °°Àº ÁßÀç ½Ã¼úÀ» Áö¿øÇϸç, ÀÌ ÀϹÝÀûÀÎ ½ÉÇ÷°ü ÁúȯÀ» °ü¸®Çϰí ȯÀÚÀÇ ½ÉÀå °Ç°°ú »îÀÇ ÁúÀ» Çâ»ó½ÃŰ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ȯÀÚÀÇ ½ÉÀå °Ç°°ú »îÀÇ Áú Çâ»ó¿¡ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.
ÃßÁ¤ ±â°£ µ¿¾È ¾Æ½Ã¾ÆÅÂÆò¾çÀÌ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº Áß±¹, Àεµ, ÀϺ»°ú °°Àº ±¹°¡¿¡¼ ½ÉÀå °ü·Ã Áúº´ Ä¡·á¿¡ ÃÊÁ¡À» ¸ÂÃá ´Ù¾çÇÑ ÀÇ·á ±â¼ú ȯ°æÀ» Æ÷ÇÔÇϰí ÀÖ½À´Ï´Ù. ÀÌ ±Þ¼ºÀåÇÏ´Â ½ÃÀåÀº ½ÉÀå ¸®µë °ü¸® ÀåÄ¡, ½ºÅÙÆ®, Áø´Ü µµ±¸ µîÀÇ ¹ßÀüÀÌ Æ¯Â¡ÀÔ´Ï´Ù. ¶ÇÇÑ, ½ÉÇ÷°ü Áúȯ Áõ°¡, ÀÇ·á ÀÎÇÁ¶óÀÇ °³¼±, Çõ½ÅÀûÀÎ ÀÇ·á ¼Ö·ç¼ÇÀÇ Ã¤Åà Áõ°¡ µîÀÇ ¿äÀÎÀÌ ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ±â¼ú Çõ½Å°ú ÀÇ·á ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ¾Æ½Ã¾ÆÅÂÆò¾çÀº ½ÉÇ÷°ü ±â±â ¼ö¿ä°¡ ±ÞÁõÇÏ´Â °ÍÀ» ¸ñ°ÝÇϰí ÀÖ½À´Ï´Ù.
ºÏ¹Ì ½ÃÀåÀº ¹Ì±¹°ú ij³ª´Ù°¡ ÁÖ¿ä ±â¿© ±¹°¡·Î, °ß°íÇÏ°í ¼º¼÷ÇÑ »óȲÀ¸·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È ¼öÀͼº ÀÖ´Â ¼ºÀåÀ» ÀÌ·ê °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÷´Ü ÀÇ·á ±â¼ú·Î À¯¸íÇÑ ÀÌ ½ÃÀåÀº ½É¹ÚÁ¶À²±â, Á¦¼¼µ¿±â, ½ºÅÙÆ®, ¿µ»ó µµ±¸ µî ´Ù¾çÇÑ ½ÉÇ÷°ü ÀåÄ¡¸¦ º¸À¯Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ³ôÀº ÀÇ·áºñ ÁöÃâ, Á¤±³ÇÑ ÀÇ·á ÀÎÇÁ¶ó, ´ë±Ô¸ð ȯÀÚ Ç® µîÀÇ ¿äÀÎÀÌ ½ÃÀå ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù. Àúħ½ÀÀû ¼ö¼úÀÇ Çõ½ÅÀº ¿¬±¸°³¹ß¿¡ ´ëÇÑ °Á¶¿Í ÇÔ²² ÃÖ÷´Ü ½ÉÇ÷°ü ±â¼ú ºÐ¾ß¿¡¼ ÀÌ Áö¿ªÀÇ ¸®´õ½Ê¿¡ ±â¿©Çϰí ÀÖÀ¸¸ç, ȯÀÚ ¿¹ÈÄ °³¼±¿¡ ÃÊÁ¡À» ¸ÂÃá °æÀïÀûÀÎ ½ÃÀå ȯ°æÀ» Á¶¼ºÇϰí ÀÖ½À´Ï´Ù.
According to Stratistics MRC, the Global Cardiovascular Devices Market is accounted for $65.66 billion in 2023 and is expected to reach $127.15 billion by 2030 growing at a CAGR of 9.9% during the forecast period. Cardiology devices are medical equipment intended to diagnose, treat, and monitor diseases and cardiovascular systems. They play a vital role in healthcare by treating a range of cardiovascular disorders, including arrhythmias, coronary artery disease, and heart failure. Some of these devices are pacemakers, defibrillators, imaging equipment, monitoring systems, and catheters. Their importance derives from their capacity to provide effective treatment initiatives, facilitate precise diagnosis, and improve patient outcomes-all of which significantly raise standards for cardiac health and save lives.
According to the World Health Organization, around 75% of the cardiovascular diseases related deaths occur in low and middle income countries.
The rising prevalence of cardiovascular diseases (CVDs) such heart failure, arrhythmias, and coronary artery disease (CADD) is attributed to several factors, including sedentary lifestyles, unhealthy diets, tobacco use, and ageing populations. This escalating disease burden necessitates a greater demand for innovative cardiovascular devices and technologies. Devices such as implantable cardioverter-defibrillators (ICDs), pacemakers, drug-eluting stents, and cardiac monitoring devices play pivotal roles in diagnosing, treating, and managing various cardiovascular conditions. These advanced technologies aid in improving patient outcomes, reducing mortality rates, and enhancing the overall quality of life for affected individuals. Therefore, there is an increasing demand for market expansion.
Heightened regulatory scrutiny, demanding safety standards, and the necessity for extensive clinical trials significantly elevate R&D costs and timelines. These barriers disproportionately affect smaller companies and start-ups, limiting their ability to enter the market and innovate. Established players also encounter impediments, requiring substantial investments in R&D. These mounting hurdles in R&D hinder the timely introduction of novel cardiovascular devices, impeding innovation and market growth.
Telemedicine and remote monitoring facilitate continuous patient care by enabling remote monitoring of vital signs, cardiac rhythms, and other relevant data in real-time. For cardiovascular patients, this offers the convenience of home-based monitoring, reducing hospital visits, and enhancing accessibility to healthcare. Advanced wearable devices, mobile apps, and connected platforms allow healthcare professionals to remotely assess patients' conditions, provide timely interventions, and offer personalised care, ultimately improving patient outcomes. The integration of telemedicine and remote monitoring in cardiovascular also opens avenues for innovation, driving the development of more sophisticated, user-friendly, and effective cardiovascular devices tailored for remote monitoring and telehealth applications.
Evolving and stringent regulatory requirements can result in prolonged approval processes, increased compliance costs, and heightened barriers for new device introductions. These regulations may inhibit innovation and market entry, particularly for smaller companies with limited resources to navigate complex regulatory landscapes. Also, regulatory changes or uncertainties might disrupt existing market strategies and investments, impacting product development timelines and market competitiveness.
The COVID-19 pandemic significantly affected the cardiovascular device market in various ways. Initially, the focus shifted towards managing the pandemic, causing a decline in elective procedures and diagnostics for cardiovascular conditions due to healthcare resource reallocation and patient reluctance to seek non-emergency care. Supply chain disruptions and manufacturing constraints also impacted device availability. However, the pandemic accelerated the adoption of telemedicine and remote monitoring solutions, driving innovation in digital health for cardiovascular care. As vaccination rates increased and healthcare systems adapted to the new normal, there was a gradual rebound in elective procedures.
The Diagnostic and Monitoring Devices segment is estimated to hold the largest share, due to the advanced technologies designed to detect, monitor, and assess cardiovascular conditions. They enable real-time monitoring of heart rhythms, blood pressure, and other vital signs, aiding in the early detection of abnormalities and facilitating continuous patient care. Additionally, these devices play a pivotal role in diagnosing various cardiovascular diseases, providing healthcare professionals with crucial data for accurate assessments, personalised treatment strategies, and improved patient outcomes, ultimately contributing to better management and care of cardiac
The Coronary Artery Disease (CAD) segment is anticipated to have lucrative growth during the forecast period. Coronary artery disease (CAD) is a narrowing or blockage of your coronary arteries, which supply oxygen-rich blood to the heart. These devices help restore blood flow to the heart, alleviate symptoms, and reduce the risk of heart attacks. CAD-specific devices aid in interventions such as percutaneous coronary interventions (PCI) and coronary artery bypass grafting (CABG), playing a pivotal role in managing this prevalent cardiovascular condition and improving patients' cardiac health and quality of life.
Asia Pacific commanded the largest market share during the extrapolated period. It encompasses a diverse landscape of medical technologies focused on treating heart-related conditions across countries like China, India, Japan, and others. This rapidly growing market features advancements in cardiac rhythm management devices, stents, diagnostic tools, and more. Moreover, factors such as rising cardiovascular diseases, improving healthcare infrastructure, and increasing adoption of innovative medical solutions contribute to the market's expansion. With a blend of technological innovation and growing healthcare awareness, the Asia Pacific region is witnessing a surge in demand for cardiovascular devices.
North America is expected to witness profitable growth over the projection period, owing to its robust and mature landscape, encompassing the United States and Canada as key contributors. Known for its advanced medical technologies, this market hosts a wide array of cardiovascular devices, including pacemakers, defibrillators, stents, and imaging tools. Furthermore, factors such as high healthcare spending, sophisticated healthcare infrastructure, and a large patient pool drive market growth. Innovations in minimally invasive procedures, coupled with a strong emphasis on research and development, contribute to the region's leadership in cutting-edge cardiovascular technologies, fostering a competitive market environment with a focus on improving patient outcomes
Some of the key players in the Cardiovascular Devices Market include Abbott, Cardinal Health, Boston Scientific Corporation, General Electric (GE Healthcare), Medtronic, W. L. Gore & Associates, Inc., Biotronik, Canon Medical Systems Corporation, Siemens Healthcare GmbH., Edwards Lifesciences Corporation, LivaNova PLC, B. Braun Melsungen AG, Johnson & Johnson Services, Inc., Terumo Cardiovascular Systems Corporation, Philips Healthcare, MicroPort Scientific Corporation, Lepu Medical Technology(Beijing)Co Ltd, Occlutech, Getinge AB and AtriCure, Inc.
In October 2022, Medtronic plc received United States FDA approval for expanded labeling of a cardiac lead that taps into the heart's natural electrical system, giving patients needed therapy while avoiding complications sometimes associated with traditional pacing methods, such as cardiomyopathy.
In October 2022, Biosense Webster, Inc., part of Johnson & Johnson MedTech launched the HELIOSTAR Balloon Ablation Catheter in Europe. The HELIOSTAR Balloon Ablation Catheter is indicated for use in the catheter-based cardiac electrophysiological mapping (stimulating and recording) of the atria and, when used with a compatible multi-channel RF generator, for cardiac ablation.
List Of Tables